Trial Profile
An ancillary study of "a randomized phase 2 study of TS-1 versus CDDP+VNR for adjuvant therapy in patients with non-small cell lung cancer(UMIN000027435)" - investigation of effect prediction bio-marker for adjuvant therapy.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 26 May 2022
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacodynamics; Pharmacogenomic
- Acronyms LOGIK1702-A
- 25 May 2022 Status changed from recruiting to discontinued.
- 01 Jun 2017 Status changed from not yet recruiting to recruiting.
- 24 May 2017 New trial record